Rosetta Genomics

Company Overview

Snapshot

Founded in March 2000 by Isaac Bentwich, Rosetta Genomics operated with 51–200 employees. The company raised a total of $6M across two funding rounds from three investors. In December 2017, Rosetta Genomics was acquired by Genoptix.

Business overview

Rosetta Genomics specializes in developing and commercializing microRNA-based and other molecular diagnostics. Leveraging an integrative research platform that combines bioinformatics and laboratory processes, the company has discovered hundreds of biologically validated novel human microRNAs. Rosetta Genomics advances multiple diagnostic programs, particularly for cancer and various other indications, to enhance accurate diagnosis, prognosis, and patient care management globally. Its RosettaGX platform utilizes blended technology platforms, including microRNA, FISH, and next-generation sequencing, alongside proprietary scientific approaches tailored for specific tumor types, to deliver clinically informative and relevant testing.

Strategic signal

In June 2018, Rosetta Genomics filed for Chapter 7 bankruptcy, following its acquisition by Genoptix in December 2017. This indicates a significant and rapid decline in the company's operational viability post-acquisition, signaling to investors the potential risks associated with integration challenges or unforeseen financial distress even after an exit event.

Company Intelligence Q&A

What was a significant exit event for Rosetta Genomics?

In December 2017, Rosetta Genomics was acquired by Genoptix, leading to its status as an inactive entity.

When did Rosetta Genomics file for bankruptcy?

Rosetta Genomics filed for Chapter 7 bankruptcy in June 2018, approximately six months after its acquisition.

When did Rosetta Genomics go public?

Rosetta Genomics completed an Initial Public Offering (IPO) in February 2007, listing on NASDAQ.

Which investors participated in Rosetta Genomics' September 2005 funding round?

In September 2005, Rosetta Genomics received funding from investors including.

What was the total capital raised by Rosetta Genomics?

Rosetta Genomics raised a total of $6M across its funding rounds.